AMICUS THERAPEUTICS, INC. — Director's Dealing 2018

Apr 4, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2018-04-02

Reporting Person: Andrews Kurt J. (SVP, Human Resources)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-02	Common Stock	M	5000	$6.13	Acquired	45469	Direct
2018-04-02	Common Stock	S	5000	$14.2686	Disposed	40469	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-02	Stock Options (right to buy)	$6.13	M	5000	Disposed	2026-02-01	Common Stock (5000)	Direct

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.00 to $14.76. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on February 1, 2017. The remaining options began to vest and become exercisable in a series of thirty-five successive equal monthly installments on March 1, 2017, with the final installment vesting on February 1, 2020.